Compositions and methods for treating alzheimer's disease
US-2024376452-A1 · Nov 14, 2024 · US
RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions
US9476047B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9476047-B2 |
| Application number | US-201514859484-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 21, 2015 |
| Priority date | Feb 15, 2008 |
| Publication date | Oct 25, 2016 |
| Grant date | Oct 25, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
First claim
Opening claim text (preview).
We claim: 1. A composition comprising an interfering RNA and a pharmaceutically acceptable carrier wherein said interfering RNA comprises a double stranded RNA having a first strand 19-49 nucleotides in length and a second strand 19-49 nucleotides in length wherein the first strand comprises SEQ ID NO: 79 or SEQ ID NO: 80. 2. The composition of claim 1 , wherein the first strand and the second strand are each 19-27 nucleotides in length. 3. The composition of claim 2 , wherein the first strand and the second strand are each 19-25 nucleotides in length. 4. The composition of claim 3 , wherein the first strand and the second strand are each 19-23 nucleotides in length. 5. The composition of claim 1 , wherein the interfering RNA molecule has blunt ends. 6. The composition of claim 1 , wherein at least one strand of the interfering RNA molecule comprises a 3′ overhang. 7. The composition of claim 6 , wherein the 3′ overhang comprises about 1 to about 6 nucleotides. 8. The composition of claim 7 , wherein the 3′ overhang comprises 2 nucleotides. 9. The composition of claim 1 , wherein the interfering RNA molecule comprises at least one modified nucleotide. 10. The composition of claim 9 wherein the modified nucleotide is a 2′-modified nucleotide. 11. The composition of claim 10 wherein the 2′-modified nucleotide is selected from the group consisting of: 2′-deoxy nucleotide, 2′-amino nucleotide, 2′-O-methyl nucleotide, 2′-methoxyethyl nucleotide. 12. The composition of claim 1 wherein the sense strand or the antisense strand contains a phosphorothioate linkage. 13. The composition of claim 1 , wherein the interfering RNA molecule is a siRNA.
Assignees
Inventors
Classifications
- A61K31/713Primary
Double-stranded nucleic acids or oligonucleotides · CPC title
Ophthalmic agents · CPC title
against receptors or cell surface proteins · CPC title
Antisense · CPC title
Antiglaucoma agents or miotics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9476047B2 cover?
- RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.
- Who is the assignee on this patent?
- Arrowhead Res Corp, Arrowhead Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/713. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).